^
Association details:
| Biomarker: | PALB2 deletion |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
Published date:
05/27/2021
Excerpt:
Biallelic, but not mono-allelic, PALB2 deleterious alterations were associated with clinical benefit. In the ATM cohort, loss of ATM protein by immunohistochemistry associated with better outcome...Overall, APCs with...PALB2 biallelic loss and loss of ATM immunohistochemical expression associated with clinical benefit.
DOI:
10.1158/2159-8290.CD-21-0007
